Size alone should not determine biopsy decision, RSNA study finds
Radiologists will often not biopsy small lesions because they assume the lesions are benign. But the decision to do so could mean missing malignant cases, according to a scientific session presented Sunday at the RSNA 2009 meeting.
Radiologists will often not biopsy small lesions because they assume the lesions are benign. But the decision to do so could mean missing malignant cases, according to a scientific session presented Sunday at the RSNA 2009 meeting.
Previously published literature shows a low malignancy rate for small MRI-detected masses, but a new study presented by Dr. Meera Sekar, a radiologist in Jamaica Plain, MA, shows even small lesions can be malignant.
In the study, Sekar and colleagues looked at 68 masses detected on MRI. Of all the masses, 36 were 5 mm and 32 were 3 to 4 mm. Biopsy revealed malignancy in 15 masses, for an overall malignancy rate of 22%. Of all the masses less than 5 mm, nine were malignant.
The decision to biopsy lesions less than 5 mm in size detected via MRI should be made based on MRI features and patient risk factors, Sekar said.
"No difference in proportion of malignancies was found based on shape or margins," she said.
However, there was a higher proportion of malignancies in patients who had MR for follow-up of a previous MRI finding and those with washout kinetics, she said.
"Radiologists should take the small lesions seriously," said Dr. Elizabeth Morris, moderator of the session.
Lesions less than 5 mm are not always benign; cancers have to grow and their size can start at something as small as 5 mm, said Morris, director of breast MRI and breast imaging research at Memorial Sloan-Kettering Cancer Center in New York.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
